SANTA CLARA, Calif., Oct. 11, 2011 – Agilent Technologies, Inc. (NYSE: A) today introduced its ZORBAX Rapid Resolution High Definition 300SB-C8, 1.8 µm columns for liquid chromatography. The new 1.8 µm particles expand Agilent’s range of wide-pore, 300Å columns for better recovery, resolution and scalability in protein analysis.
These RRHD columns are used in ultra-high-performance liquid chromatography (UHPLC) to analyze the primary structure of proteins, to confirm protein identity, to quantify post-translational modifications, and to provide impurity profiles for biotherapeutic protein discovery and production.
“Faster and higher performance UHPLC protein separations are now available, with added resolution from a reversed-phase column with sub-2-µm particles,” said Phil Stremple, Agilent chemistries marketing manager. “This new ZORBAX column, with C8 functionality, is the second of a series of wide-pore RRHD columns for protein applications.”
The 1.8 µm particle size and 300Å pore size brings UHPLC efficiency, resolution and robust quantitation to reversed-phase protein separations. Additionally, the columns are stable up to 1,200 bar. Agilent’s proven StableBond technology delivers symmetrical peaks even at low pH when using trifluoroacetic or formic acid mobile-phase modifiers, without compromising column life.
Baselines are steady with UV and MS detection. The new columns are available in lengths of 50 mm and 100 mm to meet the needs of analysts for speed or resolution.
For more information, visit www.agilent.com/chem/biohplcproteins.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company’s 18,500 employees serve customers in more than 100 countries. Agilent had net revenues of $5.4 billion in fiscal 2010. Information about Agilent is available at www.agilent.com.
Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.
Louise Muttram
Account Manager
dna medical communications
Fox Court, 14 Grays Inn Road
London, WC1X 8WS
United Kingdom
T:+44 (0)20 7067 0216
F:+44 (0)844 826 8317
LMuttram@dnamedcomms.com
